Tiotropium: consider cardiovascular risk when prescribing

Precautions for the use of tiotropium (Spiriva) in patients with cardiac conditions have been revised in light of new trial data.

Tiotropium (Spiriva) is licensed as a maintenance bronchodilator treatment to relieve symptoms of COPD.
Tiotropium (Spiriva) is licensed as a maintenance bronchodilator treatment to relieve symptoms of COPD.

Previous pooled analyses suggested that tiotropium is associated with a higher risk of mortality than placebo when delivered via the Respimat soft-mist inhaler (at a dose of 5 microgram daily), but a reduced mortality risk relative to placebo when administered via the breath-actuated HandiHaler (at a dose of 18 microgram daily).

Further information
MHRA Drug Safety Update
TIOSPIR trial

The prescribing information for Spiriva Respimat had therefore recommended caution when prescribing the anticholinergic to patients with known cardiac rhythm disorders.

Now, however, the randomised, controlled double-blind TIOSPIR trial (n=17,135) has shown that there is no significant difference between the two treatments in terms of safety (hazard ratio for death from any cause for tiotropium Respimat vs tiotropium HandiHaler, 0.96; 95% CI 0.84-1.09) or efficacy (hazard ratio for first COPD exacerbation, 0.98; 95% CI 0.93-1.03) in the treatment of COPD. 

The prescribing information for both products has been updated to advise prescribers to consider the risk of cardiovascular side-effects in patients with conditions that were excluded from the TIOSPIR trial and could be affected by the anticholinergic action of tiotropium, including:

  • myocardial infarction in the last 6 months
  • unstable or life-threatening cardiac arrhythmia
  • cardiac arrhythmia requiring intervention or a change in drug therapy in the past year
  • hospitalisation for heart failure (NYHA Class III or IV) within the past year

These patients should be advised to report any worsening of cardiac symptoms during treatment.

In addition, treatment should be regularly reviewed in patients at high risk of cardiovascular events.


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.